arrow
R

Roberto Badagliacca

Sapienza University of Rome
H指数:42
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The added value of echocardiography in pulmonary arterial hypertension risk assessment an artificial intelligence machine learning–derived analysis of the ULTRA RIGHT VALUE registry

超声心动图在肺动脉高压风险评估中的附加价值:一项基于人工智能机器学习的ULTRA RIGHT VALUE注册研究分析

2026-09-170
OAAI
Bidirectional impact between cardiovascular comorbidities and heart failure: an updated position paper from the Italian society of cardiology (SIC) working group on heart failure

心血管合并症与心力衰竭的双向影响:意大利心脏病学会(SIC)心力衰竭工作组更新的立场文件

2026-08-310
PRE
Safety and efficacy of upfront triple therapy including parenteral treprostinil compared to double oral therapy in PAH (TripleTRE): study protocol for a randomised trial

upfront三联疗法(包括静脉注射曲前列尼尔)与双口服疗法在肺动脉高压中的安全性和有效性比较(TripleTRE研究):一项随机试验的研究方案

2026-01-190
PRE
The pleiotropic effects of sotatercept

sotatercept的多种效应

2025-12-200
PRE
Contemporary medical therapy for heart failure across the ejection fraction spectrum: The OPTIPHARM-HF registry
2025-12-010
OAAI
ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of reveal risk score

ASPYRE-1研究:一项意大利多中心前瞻性研究,关于肺动脉高压的死亡模式及REVEAL风险评分的验证

2025-11-290
PRE
Add-On Therapy with Parenteral Prostacyclin Analogues in Patients with Pulmonary Arterial Hypertension: Insights from the COMPERA Registry

静脉注射前列环素类似物作为附加疗法在肺动脉高压患者中的应用:COMPERA登记研究的见解

2025-10-240
OAAI
Authors’ Perspective on the International Society for Heart and Lung Transplantation Consensus Statement on Risk Stratification in Pulmonary Arterial Hypertension

作者关于国际心肺移植学会关于肺动脉高压风险分层共识声明的观点

2025-10-220
PRE
Early SGLT2i Therapy Facilitates In-Hospital ARNI Introduction Improving 6-Month Systolic Function in Patients with HFrEF

早期SGLT2i疗法有助于促进住院期间ARNI的引入,改善HFrEF患者6个月时的收缩功能

2025-10-060
OA
International Society for Heart and Lung Transplantation (ISHLT) Consensus Statement on Risk Stratification in Pulmonary Arterial Hypertension

国际心脏与肺移植学会(ISHLT)关于肺动脉高压风险分层共识声明

2025-09-050
PRE
Evaluation of non-invasive low-risk criteria in patients with connective tissue disease-associated pulmonary arterial hypertension: A 12-months analysis from the INSPECTIO study

评估非侵入性低风险标准在结缔组织病相关肺动脉高压患者中的价值:INSPECTIO研究12个月分析

2025-08-190
PRE
Impact of glomerular filtration rate estimation formulas on MECKI score performance and prognostic accuracy in heart failure: the MECKI-RENAL study

肾小球滤过率估算公式对心衰患者MECKI评分性能及预后准确性的影响:MECKI-RENAL研究

2025-08-010
PRE
Early in-hospital use of SGLT2i in heart failure patients with ischemic etiology

缺血性病因心力衰竭患者早期院内使用SGLT2i

2025-05-150
OA
Echocardiographic Parameters and Risk Prediction in Pulmonary Arterial Hypertension

超声心动图参数可增强肺动脉高压的风险预测评分:PVDOMICS网络的研究发现

CHEST
IF8.6
2025-04-120
PRE
Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus

中危肺动脉高压患者治疗的证据空白: 专家共识

2024-12-012
PRE